ERLN-TB expert opinion on the use of the rapid molecular assays for the diagnosis of tuberculosis and detection of drug resistance
According to this report, the use of rapid molecular assays has diagnostic value in tuberculosis (TB) identification and detection of drug resistance, although there is not enough evidence to recommend these tools in all populations and situations and they should not replace standard diagnostic methods.
Healthcare system factors influencing treatment results of patients with multidrug-resistant tuberculosis
Qualitative research was carried out in four EU countries to try to identify the factors of a healthcare system that are key to achieving good treatment results for patients with multidrug-resistant tuberculosis.
Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA
This report presents the main findings of an ECDC project to assess the burden of infectious diseases among migrants in the EU/EEA based on available data for specific diseases: human immunodeficiency virus (HIV), tuberculosis (TB), hepatitis B, hepatitis C, gonorrhoea, syphilis, measles and rubella, malaria and Chagas disease.
Assessing the burden of key infectious diseases affecting migrant populations in the EU/EEA: Executive summary
Tuberculosis in Europe: from passive control to active elimination – high- and low-incidence countries
This four-page evidence brief provides an overview of tuberculosis control and elimination efforts in the EU/EEA, with a particular focus on the epidemiological differences between high- and low-incidence countries.
Mathematical modelling of programmatic screening strategies for latent tuberculosis infection in countries with low tuberculosis incidence
Elimination of tuberculosis (TB) requires the management of latent tuberculosis infection (LTBI) in key populations. Thus, people with LTBI need to be diagnosed and treated with appropriate regimens. It is unknown how different screening and treatment strategies of key populations affect TB transmission and progress toward elimination.
Cost-effectiveness analysis of programmatic screening strategies for latent tuberculosis infection in the EU/EEA
The elimination of tuberculosis (TB) in Europe will require the management of latent tuberculosis infection (LTBI) in key populations. Management of LTBI requires the identification and adequate treatment of infected people. It is currently unknown how screening and treatment of key populations should be best organised to have the highest impact with the available resources.